A Bermuda based clinical-stage company announced positive efficacy data from testing AM-301 nasal spray in vitro against a SARS-COV-2 coronavirus infection.
This study by Auris Medical Holding Ltd. reported up to 99.4 percent reduction of viral titer in human epithelial cell culture.
Read More
